Johnson & Johnson JNJ

$253.91 +5.30 (2.13%)

Valuation

Market cap
635,562,368,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.07
Forward PE
23.40
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,629,150
Avg volume
6,718,360
Day's range
$248.78 – $253.94
Shares out
2,409,898,000
Stochastic %K
18%
Beta
0.21
Analysts
Strong Sell
Price target
$282.76

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Ryan071236 Oct 14, 6:04 PM
$JNJ should explode to higher highs before coming back down a bit. buy some calls, then cash out
0 replies
EarningsDesk Oct 14, 5:34 PM
Yesterday, 5 reports: $JNJ beat — $2.59 vs $2.52 est. $C beat — $2.83 vs $2.62 est. $DPZ beat — $4.60 vs $4.39 est. $FBK in line — $1.21 vs $1.21 est. $WFC beat — $1.87 vs $1.86 est. 4 beats, 1 in line.
0 replies
chursinow62 Oct 14, 5:26 PM
$JNJ Three big institutional houses loading here
0 replies
SellasgpsCurativeBAT11 Oct 14, 5:23 PM
$SLS $JNJ Don’t need to wait. Johnson & Johnson (JNJ) can comfortably afford single-deal buyouts of $15 billion to $20 billion using its existing cash and annual organic cash flows. If the company utilizes its premium credit rating to issue new debt, its maximum aggregate acquisition capacity stretches closer to $40 billion to $50 billion without seriously threatening its investment-grade status. ✌️🙏❤️‍🩹
1 replies
Baddb Oct 14, 4:37 PM
$JNJ started shorts again
0 replies
stockanalysis_ Oct 14, 4:21 PM
A nice flight to safety into Healthcare today... $LLY +4.06% $MRK +3.88% $ABBV +3.31% $AMGN +3.13% $JNJ +1.32%
0 replies
OptionRunners Oct 14, 3:46 PM
$JNJ looks like these calls were just closed for $1.85
0 replies
chursinow62 Oct 14, 3:42 PM
$JNJ Cramers charitable trust adding
0 replies